Join us to learn how technological innovation can be applied to late phase research studies
Register today to learn how an appropriate technology platform can support the use of RWD sources throughout the study lifecycle and serve as a powerful tool when designed with the study protocol in mind. Once the framework is developed, this fit-for-purpose model can be leveraged to support late phase study planning, recruitment, and execution across multiple products and studies.
With demand increasing for new and innovative approaches to late phase research, technology solutions and access to RWD are at the forefront of creating efficiencies in all stages of study design and implementation. But what steps should you take in study planning to ensure these efficiencies are effectively applied? And how can you partner with CROs to ensure that the secondary and primary data are pulled through the appropriate technology solutions for optimal use?
The enrolment process for clinical trials is notoriously inefficient. Sponsors struggle to identify the best investigator sites and enrol the target number of patients amid competing trials. Part of this inefficiency stems from the traditional recruitment model of relying on selected Key Opinion Leaders (KOLs) to recruit patients.
With the right information about how many patients are eligible—and where they are located—this model can be turned on its head. EHR data can improve this process dramatically.
Key insights include:
- The use of electronic health record (EHR) data across the life cycle of late phase research studies
- How RWD can be optimised and analysed using technology to enhance clinical research efficiency and provide the real world evidence (RWE) necessary for stakeholder engagement
- Technology solution considerations for optimising RWD assets supported by a fully integrated approach
Michael Cook, MSc, MSPH, PhD
Principal, Epidemiology, ICON Commercialisation & Outcomes
Dr. Cook has 15 years of pharmaceutical company experience holding positions of increasing responsibility at Merck, Pfizer and Shire. His area of methodological expertise is in the analysis of large health care databases to conduct real world evidence (RWE) studies.
Bill Row, MBA, MS
Divisional Principal, Real World Evidence, ICON Commercialisation & Outcomes
Bill has over 17 years of experience in study design and execution. He is a recognised leader in the design, operational strategy, and commercial applications of RWE late phase studies for both pharma companies and CROs. His has held leadership roles in clinical operations, project management, and strategy/innovation.
This program is intended for professionals from pharmaceutical, biotech, and medical device companies involved in:
- Medical affairs
- Epidemiology (EPI)
- Health economics and outcomes research (HEOR)
- Market access